Ullrich A - Search Results

1

Distracting painful injuries associated with cervical spinal injuries in blunt trauma.

Ullrich A, Hendey GW, Geiderman J, Shaw SG, Hoffman J, Mower WR. Ullrich A, et al. Acad Emerg Med. 2001 Jan;8(1):25-9. doi: 10.1111/j.1553-2712.2001.tb00542.x. Acad Emerg Med. 2001. PMID: 11136143 Free article.

2

Pancreatic cancer growth is inhibited by blockade of VEGF-RII.

Büchler P, Reber HA, Ullrich A, Shiroiki M, Roth M, Büchler MW, Lavey RS, Friess H, Hines OJ. Büchler P, et al. Among authors: ullrich a. Surgery. 2003 Nov;134(5):772-82. doi: 10.1016/S0039-6060(03)00296-4. Surgery. 2003. PMID: 14639356

3

Flk-1 as a target for tumor growth inhibition.

Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK. Strawn LM, et al. Among authors: ullrich a. Cancer Res. 1996 Aug 1;56(15):3540-5. Cancer Res. 1996. PMID: 8758924

4

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. Fong TA, et al. Among authors: ullrich a. Cancer Res. 1999 Jan 1;59(1):99-106. Cancer Res. 1999. PMID: 9892193

5

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.

Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Millauer B, et al. Among authors: ullrich a. Nature. 1994 Feb 10;367(6463):576-9. doi: 10.1038/367576a0. Nature. 1994. PMID: 8107827

6

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington. Laird AD, et al. Among authors: ullrich a. Cancer Res. 2000 Aug 1;60(15):4152-60. Cancer Res. 2000. PMID: 10945623

7

Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.

Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ. Shawver LK, et al. Among authors: ullrich a. Clin Cancer Res. 1997 Jul;3(7):1167-77. Clin Cancer Res. 1997. PMID: 9815796

8

Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.

Vajkoczy P, Thurnher A, Hirth KP, Schilling L, Schmiedek P, Ullrich A, Menger MD. Vajkoczy P, et al. Among authors: ullrich a. Oncologist. 2000;5 Suppl 1:16-9. doi: 10.1634/theoncologist.5-suppl_1-16. Oncologist. 2000. PMID: 10804086 Free article.

9

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.

Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Erber R, et al. Among authors: ullrich a. FASEB J. 2004 Feb;18(2):338-40. doi: 10.1096/fj.03-0271fje. Epub 2003 Dec 4. FASEB J. 2004. PMID: 14657001

10

Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor.

Strawn LM, Mann E, Elliger SS, Chu LM, Germain LL, Niederfellner G, Ullrich A, Shawver LK. Strawn LM, et al. Among authors: ullrich a. J Biol Chem. 1994 Aug 19;269(33):21215-22. J Biol Chem. 1994. PMID: 8063742 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

746 results

Search Page